Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by BlaineBorgon Jul 10, 2021 3:33pm
316 Views
Post# 33526919

Cyndi Edwards @ Streetwise Live! Asks The #1 Question

Cyndi Edwards @ Streetwise Live! Asks The #1 QuestionCyndi Edwards: Dr. Nutt, on a scale from 1 to 10, how hopeful are you about the possibilities with DMT and helping stroke victims?

Dr Nutt: I'm saying I'm currently at a 3, but I'm hoping once we've shown we can do it safely and started trials with patients next year, and I'm hoping I will move up to a 5 or a 6.

There's your best odds given by an expert in the field. 30% to maybe 50% or 60% given the outcome of a Phase 1 clinical trial next year. Dr. Nutt also noting that 99% of all stroke clinical trials have failed.

Meanwhile, we wait and wait and wait for the results of the IPF and Chronic Cough study that remains the best chance of success for Algernon Pharmaceuticals in the foreseeable future. 




BB
<< Previous
Bullboard Posts
Next >>